Marco Donia, Professor of Clinical Oncology at University of Copenhagen, shared on LinkedIn:
“TIL therapy without systematic IL-2: a step toward more accessible cell therapy”
High-dose IL-2 made TIL therapy work, but its toxicity has limited both the patients who can tolerate it and the centres able to deliver it.
37 patients with ICI-resistant advanced melanoma treated with amsoki-cel (OBX-115), an investigational TIL product engineered to express membrane-bound IL-15 regulated by oral acetazolamide.
No systemic IL-2 after infusion. IL-2 is still used in the pre-REP phase of manufacturing, but mbIL15 removes it from the expansion phase.
Key points (Two early-phase trials, 15 patients treated at the recommended phase 2 dose (RP2D):
- ORR 66.7% (10/15; 95% CI 38-88%), 2 complete responses.
- Median PFS 8.1 months (95% CI 3.9 to not estimable), median follow-up 8.3 months (4.1-21.4).
- No dose-limiting toxicities, no ICU admissions, no ICANS and no treatment-related deaths across 37 patients; one grade 3 CRS. Grade 3 or higher toxicity predominantly hematologic (neutropenia 64.9%), serious non-hematologic events in 13.5%.
- All 15 patients at RP2D received low-dose lymphodepletion, and all acetazolamide re-dosing was given in the outpatient setting.
Removing systemic IL-2, lowering the intensity of lymphodepletion and moving re-dosing to the outpatient clinic would make the regimen deliverable in many more departments. Tumour procurement, individualized manufacturing and lymphodepletion itself remain real barriers.
Two questions for the next step:
- Will the responses hold? Longer follow-up of these same patients answers this first: . Agni-01 cohort 3 (NCT06060613) then tests the response rate in a larger sample.
- Will a lighter regimen widen who gets treated? Plausible, and so far untested
Reviewed for Nature Medicine, and post written together with Yago Garitaonaindia.
Congratulations to Rodabe N. Amaria, Jason Chesney, Allison Betof and all the investigators, and Parameswaran Hari and the Obsidian Therapeutics team. Above all, thanks to the patients who agreed to take part in these first-in-human studies.”
Title: Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
Authors: Rodabe N. Amaria, Jason A. Chesney, Allison S. Betof, Gino K. In, Alexander N. Shoushtari, Tirrell T. Johnson, Omid Hamid, Yazan Samhouri, Michael A. Davies, Hussein A. Tawbi, Isabella C. Glitza Oliva, Bulent Arman Aksoy, Amanda M. Kelly, Raina Duan, Prakash Prabhakar, Giridharan Ramsingh, Madan Jagasia, Parameswaran Hari.
You can also read:
